LABHIGH SIGNALOPERATIONAL10-K

LAB completed a major divestiture by selling SomaLogic to Illumina in June 2025, fundamentally restructuring the business with massive debt reduction and significant operational downsizing.

This represents a transformational corporate event where LAB divested a major business unit (SomaLogic) that it had only acquired through merger in January 2024, suggesting either strategic pivot or financial necessity. The transaction appears to have generated substantial cash proceeds used to eliminate nearly all debt, but also resulted in a much smaller operational footprint with significantly reduced revenue-generating capacity.

Comparing 2026-03-16 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

The divestiture created a dramatically smaller but financially healthier company, with total debt plummeting 99.5% from $63.5M to $299K while current liabilities increased 64.4% likely due to transaction-related obligations. Revenue-related metrics declined substantially with accounts receivable down 60%, inventory down 51%, and gross profit falling 49.5%, indicating a much smaller business scale post-divestiture. Despite the operational downsizing, the company improved its loss profile significantly with net losses narrowing 46.1% and operating cash flow losses improving 48.2%, suggesting the remaining business is more efficient and the debt elimination strengthened the balance sheet considerably.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
-99.5%
$63.5M→$299K

Debt reduced 99.5% — deleveraging strengthens balance sheet and reduces financial risk.

Current Liabilities
Balance Sheet
+64.4%
$65.9M→$108.3M

Current liabilities surged 64.4% — significant near-term obligations; verify ability to meet short-term debt.

Accounts Receivable
Balance Sheet
-60%
$33.6M→$13.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

R&D Expense
P&L
-58.4%
$62.4M→$26.0M

R&D spending cut 58.4% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
-51%
$40.7M→$20.0M

Inventory drawn down 51% — strong sell-through or deliberate destocking; watch for supply constraints.

Gross Profit
P&L
-49.5%
$84.3M→$42.5M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Cash Flow
Cash Flow
+48.2%
-$143.5M→-$74.3M

Operating cash flow surged 48.2% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+46.1%
-$138.9M→-$74.9M

Net income grew 46.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+37.1%
-$175.2M→-$110.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

SG&A Expense
P&L
-29.8%
$156.6M→$109.9M

SG&A reduced 29.8% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-11
ADDED
As of March 12, 2026, there were 390,071,506 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 42 ITEM 7A.
export controls and tariffs, potential growth opportunities, market growth expectations, the effects of competition, cost structure optimization, acceleration of growth, potential merger and acquisition activity and restructuring plans (including expense reduction activities, modifications to the scope of our proteomic and genomics businesses and discontinuing of certain product lines), our expectations regarding the benefits and integration of acquired businesses and/or products and the transaction with Illumina, Inc.
( Illumina ), including the financial impact of the transaction, potential earnout payments and royalty streams, potential integration, restructuring and transition-related disruption from the transaction, and potential stockholder litigation from the transaction.
On June 22, 2025, we entered into a Stock Purchase Agreement (the Purchase Agreement ) with Illumina.
+7 more — sign up free →
REMOVED
As of March 2, 2025, there were 378,986,362 shares of the registrant s common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 57 ITEM 7A.
Forward-looking statements include information concerning our possible or assumed future cash flow, revenue, sources of revenue and results of operations, cost of product revenue and product margin, operating and other expenses, unit sales and the selling prices of our products, business strategies, financing plans, expansion of our business, investments to expand our customer base, plans for our products, competitive position, industry environment, anticipated National Institutes of Health funding pressures, the expected effect from U.S.
export controls and tariffs, potential growth opportunities, market growth expectations, the effects of competition, cost structure optimization, acceleration of growth, potential merger and acquisition (M A) activity and restructuring plans (including expense reduction activities, modifications to the scope of our proteomic and genomics businesses and discontinuing of certain product lines) and our expectations regarding the benefits and integration of acquired businesses and/or products.
On January 5, 2024, we completed our merger with SomaLogic, Inc.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →